Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion type Assertion NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_head.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion description "[More significantly, the combination of intravenously administered ligand-liposome-AS HER-2 ODN and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_provenance.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion evidence source_evidence_literature NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_provenance.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion SIO_000772 12435858 NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_provenance.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion wasDerivedFrom befree-20150227 NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_provenance.
- NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_assertion wasGeneratedBy ECO_0000203 NP380339.RAQgySxmBy9t1sILCgZTSiNgAc_xgjdH6X1tiYbqQU5rs130_provenance.